CO2022015448A2 - Compuestos de azalactama como inhibidores de hpk1 - Google Patents

Compuestos de azalactama como inhibidores de hpk1

Info

Publication number
CO2022015448A2
CO2022015448A2 CONC2022/0015448A CO2022015448A CO2022015448A2 CO 2022015448 A2 CO2022015448 A2 CO 2022015448A2 CO 2022015448 A CO2022015448 A CO 2022015448A CO 2022015448 A2 CO2022015448 A2 CO 2022015448A2
Authority
CO
Colombia
Prior art keywords
compounds
azalactam
hpk1 inhibitors
salts
hpk1
Prior art date
Application number
CONC2022/0015448A
Other languages
English (en)
Inventor
Mehran Jalaie
Rebecca Anne Gallego
Sajiv Krishnan Nair
Jamison Bryce Tuttle
Michele Ann Mctigue
Bel Matthew L Del
Ru Zhou
Mingying He
Robert Steven Kania
Dahui Zhou
Joyann Barber
Sujin Cho-Schultz
Anne-Marie Dechert Schmitt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO2022015448A2 publication Critical patent/CO2022015448A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la Fórmula general I I y sales farmacéuticamente aceptables de los mismos, en los que R1, R2, R3a, R3b y R4 son como se definen en el presente documento, a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos de uso de dichos compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, incluido el cáncer.
CONC2022/0015448A 2020-05-01 2022-10-28 Compuestos de azalactama como inhibidores de hpk1 CO2022015448A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063018689P 2020-05-01 2020-05-01
PCT/IB2021/053522 WO2021220185A1 (en) 2020-05-01 2021-04-28 Azalactam compounds as hpk1 inhibitors

Publications (1)

Publication Number Publication Date
CO2022015448A2 true CO2022015448A2 (es) 2022-11-18

Family

ID=75769663

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015448A CO2022015448A2 (es) 2020-05-01 2022-10-28 Compuestos de azalactama como inhibidores de hpk1

Country Status (18)

Country Link
US (2) US11684616B2 (es)
EP (1) EP4143186A1 (es)
JP (1) JP7303948B2 (es)
KR (1) KR20230003128A (es)
CN (1) CN115698004A (es)
AR (1) AR121985A1 (es)
AU (1) AU2021265578B2 (es)
CA (1) CA3181415A1 (es)
CL (1) CL2022003007A1 (es)
CO (1) CO2022015448A2 (es)
CR (1) CR20220548A (es)
EC (1) ECSP22084264A (es)
IL (1) IL297838A (es)
MX (1) MX2022013401A (es)
PE (1) PE20230323A1 (es)
TW (1) TWI806043B (es)
UY (1) UY39193A (es)
WO (1) WO2021220185A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019372046B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
KR20230003128A (ko) * 2020-05-01 2023-01-05 화이자 인코포레이티드 Hpk1 억제제로서의 아잘락탐 화합물
WO2023057883A1 (en) 2021-10-05 2023-04-13 Pfizer Inc. Crystalline form of azalactam compound
TW202327595A (zh) * 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
TW201833108A (zh) 2017-03-03 2018-09-16 大陸商江蘇豪森藥業集團有限公司 醯胺類衍生物抑制劑及其製備方法和應用
EP3596075B1 (en) * 2017-03-15 2023-10-11 F. Hoffmann-La Roche AG Azaindoles as inhibitors of hpk1
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
TW201908306A (zh) * 2017-07-18 2019-03-01 大陸商南京聖和藥業股份有限公司 作為ask抑制劑的雜環化合物及其應用
US20220324835A1 (en) 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
BR112022004451A2 (pt) * 2019-09-13 2022-06-21 Nimbus Saturn Inc Antagonistas de hpk1 e usos dos mesmos
KR20230003128A (ko) * 2020-05-01 2023-01-05 화이자 인코포레이티드 Hpk1 억제제로서의 아잘락탐 화합물
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors

Also Published As

Publication number Publication date
US20240197703A1 (en) 2024-06-20
TWI806043B (zh) 2023-06-21
KR20230003128A (ko) 2023-01-05
CR20220548A (es) 2022-12-12
UY39193A (es) 2021-11-30
TW202202496A (zh) 2022-01-16
AR121985A1 (es) 2022-07-27
WO2021220185A1 (en) 2021-11-04
CL2022003007A1 (es) 2023-06-16
ECSP22084264A (es) 2022-11-30
US20220401424A1 (en) 2022-12-22
US11684616B2 (en) 2023-06-27
AU2021265578A1 (en) 2022-11-10
IL297838A (en) 2023-01-01
CN115698004A (zh) 2023-02-03
PE20230323A1 (es) 2023-02-22
MX2022013401A (es) 2022-11-14
JP7303948B2 (ja) 2023-07-05
JP2023515900A (ja) 2023-04-14
CA3181415A1 (en) 2021-11-04
EP4143186A1 (en) 2023-03-08
AU2021265578B2 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
CL2022003007A1 (es) Compuestos de azalactama como inhibidores de hpk1
UY38553A (es) Inhibidores de cdk2
CL2021001190A1 (es) Compuestos de azalactam como inhibidores de hpk1
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
UY37900A (es) Nuevos derivados de rapamicina
UY38196A (es) Inhibidores de cinasa dependientes de ciclina
NI201400102A (es) Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ECSP22038478A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
DOP2023000281A (es) Inhibidores de mutación de her2
UY39517A (es) Inhibidores de la btk
UY39303A (es) Inhibidores de mutación her2
DOP2022000203A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52
CU20140107A7 (es) Derivados macrocíclicos para el tratamiento de enfermedades
AR122805A1 (es) Inhibidores de mutación her2
ECSP24038829A (es) Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
CU20140033A7 (es) Derivados de pirrolopirimidina y purina